Articles from Rune Labs

Today, Rune Labs announced the launch of a personalized AI companion to provide always-on support for people with Parkinson’s disease. Powered by Anthropic's Claude and built on Rune Labs' proprietary longitudinal dataset, comprising millions of hours of wearable data and FDA-cleared symptom algorithms, StrivePD Guardian continuously analyzes patients' real-time data to deliver timely, context-aware guidance on symptoms, medications, daily experiences, and care goals.

Rune Labs, the leader in precision medicine for neurology, today announced Amy Gordon Franzen as its new Chief Executive Officer. Amy will lead the company’s next stage of growth, leveraging its success in Parkinson’s Disease, where it has established StrivePD as the industry’s preeminent AI platform and patient app. The company is actively expanding this platform to address additional neurological conditions, including Alzheimer’s disease and other forms of dementia. Co-founder Brian Pepin will become President, Biopharma and Platform, where he will lead Rune Labs’ expanding biopharma partnerships and research portfolio.

Rune Labs, the leader in precision medicine for neurology, today announced the appointment of Adam Pellegrini as an independent member of its Board of Directors. Pellegrini is a recognized leader in AI-driven digital health, with more than two decades of experience building and scaling platforms that bridge technology, patients, and healthcare systems. His background spans executive roles at Kaia Health, Jasper Health, CVS Health, Fitbit, Walgreens Boots Alliance, and other organizations that have shaped how digital tools support prevention, chronic disease management, and patient engagement.

Rune Labs, the leader in precision medicine for Parkinson’s disease (PD), today announced the launch of a clinical program with Parkinson’s Foundation to accelerate the discovery of genetic and digital biomarkers for PD that can be used to provide breakthroughs in diagnostics, therapy development, and clinical trial design. By mapping gene variants to real-world symptom and medication data, the study will reveal wearable-based biomarker correlations in Parkinson’s patients. The study, supported through the Global Parkinson's Genetics Program (GP2), will leverage Rune Labs’ StrivePD AI-driven software and PD GENEration, the flagship genetic testing and counseling initiative from the Parkinson’s Foundation.

Rune Labs, the leader in precision medicine for Parkinson’s Disease (PD), today launched StrivePD Guardian, a personalized care service that combines expert coaching with AI-powered symptom and risk analysis to provide continuous support for people with Parkinson’s disease and their caregivers.

Rune Labs, a leader in precision medicine for Parkinson’s Disease (PD), today previewed the results of an ongoing nine-month research program involving a diverse cohort of 138 Kaiser Permanente PD patients across California. The patients had an age range of 39 to 88 years and a mean disease duration of six years. In the care management program, all patients used an Apple Watch and Rune Labs’ StrivePD app to record their behavior for at least six hours of data per day for seven days per week. Patients with moderate severity (Hoehn and Yahr stage 2 & 3), bilateral symptoms and responsiveness to dopaminergic agents were included in the research. The research and poster were presented by Ro’ee Gilron, PhD, Lead Neuroscientist at Rune Labs, at the 2024 International Congress of Parkinson’s Disease and Movement Disorders on September 29, 2024 in Philadelphia.

Rune Labs, a precision neurology software and data company, today announced a major milestone in accelerating care management for people with Parkinson’s disease and their care support teams. As part of the StrivePD app, Rune has introduced new StrivePD-AI, Generative Artificial Intelligence (GenAI) clinical reports that provide a comprehensive, monthly outlook of disease progression along with personalized educational content to help patients, caregivers, and clinicians improve outcomes and optimize care.

Rune Labs, a leader in precision medicine for Parkinson’s disease, celebrates the signing of the National Plan to End Parkinson's Disease into law. This landmark legislation aims to unite federal and philanthropic efforts to diagnose and treat Parkinson’s Disease, helping to ensure access to necessary care for American families.

Rune Labs, a precision neurology software and data company, today announced a strategic round of $12 million, increasing the total amount raised by the company to over $42 million. The round was led by new brain disorder fund, Nexus NeuroTech Ventures, with participation from existing investors, including Eclipse, DigiTx Partners, Moment Ventures and TruVenturo GmbH. Jordi Parramon, PhD, CEO, General Partner and Co-Founder of Nexus NeuroTech Ventures and former President of Medical Devices at Verily, will join Rune Labs’ board of directors.